HYPNOTICS IN THE TREATMENT OF PSYCHIATRIC DISORDERS

安眠药治疗精神疾病

• 批准号: 7951372
• 负责人: WILLIAM Vaughn MCCALL
• 金额: $ 1.17万
• 依托单位: WAKE FOREST UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7951372
• 关键词: Antidepressive Agents; Chronic Insomnia; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Data; Development; Disease; Funding; Grant; Institution; Mental disorders; Methods; Outcome; Participant; Patients; Pharmaceutical Preparations; Quality of life; Recruitment Activity; Recurrence; Research; Research Personnel; Resources; Risk; Safety; Sleep; Sleeplessness; Source; Symptoms; Testing; United States National Institutes of Health; depressed; hypnotic; improved; interest; single episode major depressive disorder; sleeping pill; suicidal risk

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Chronic insomnia is among the most common symptoms during a major depressive episode (MDE), and the symptom of insomnia independently predicts poor quality of life (QOL), increased risk of suicide, and increased risk for recurrence of MDE. In contrast, preliminary evidence suggests that treatment of insomnia during MDE reduces the daytime symptom burden and improves QOL. Hypnotic medications (sleeping pills) are prescribed more commonly for psychiatric problems than for any other disorder, and this is not surprising since many of the newest antidepressants have little or no intrinsic sleep-inducing effect and may require that a hypnotic be prescribed along with the antidepressant. However, little is known about the efficacy and safety of combining the most commonly used antidepressant and hypnotic medications. This exploratory/development grant (R34 mechanism) will operationalize treatment of insomnia associated with MDE, will support the development of data-gathering methods for the proposed outcomes of interest, shall test the feasibility of recruiting and retaining participants, and shall provide estimates of effect sizes for adding a hypnotic medication to an antidepressant in depressed patients with insomnia.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目和 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 慢性失眠是重度抑郁发作 (MDE) 期间最常见的症状之一，失眠症状独立预测生活质量 (QOL) 不佳、自杀风险增加以及 MDE 复发风险增加。相比之下，初步证据表明，在 MDE 期间治疗失眠可减轻日间症状负担并改善生活质量。与其他任何疾病相比，安眠药（安眠药）更常用于治疗精神问题，这并不奇怪，因为许多最新的抗抑郁药几乎没有或根本没有内在的睡眠诱导作用，可能需要与抗抑郁药一起开出催眠药。然而，人们对最常用的抗抑郁药和催眠药联合使用的功效和安全性知之甚少。这项探索性/开发拨款（R34机制）将实施与MDE相关的失眠治疗，将支持针对拟议的感兴趣结果开发数据收集方法，应测试招募和保留参与者的可行性，并应提供在失眠抑郁患者的抗抑郁药物中添加催眠药物的效果大小的估计。